RLYB
Rallybio CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$43.48M
P/E Ratio
—
EPS
$-1.59
Beta
-1.20
52W High
$11.49
52W Low
$1.79
50-Day MA
$7.29
200-Day MA
$5.31
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, specifically targeting unmet medical needs in immunology and hematology. The company boasts a robust pipeline of biologic drug candidates advancing through clinical stages, supported by a seasoned management team with strong industry expertise. Strategic collaborations strengthen Rallybio's capabilities in delivering transformative treatments, ultimately aiming to enhance patient outcomes. With a clear commitment to underserved therapeutic areas, Rallybio is well-positioned to make significant contributions to the healthcare sector while paving the way toward commercial success.
Fundamentals
| Revenue (TTM) | 858,000 |
| Gross Profit (TTM) | $-17.54M |
| EBITDA | $-31.27M |
| Operating Margin | -2888.00% |
| Return on Equity | -15.00% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.15 |
| Book Value | $10.97 |
| Price-to-Book | 0.77 |
| Price-to-Sales (TTM) | 50.68 |
| EV/Revenue | - |
| EV/EBITDA | -1.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 484.20% |
| Shares Outstanding | $5.29M |
| Float | $2.71M |
| % Insiders | 4.16% |
| % Institutions | 63.65% |
Analyst Ratings
Consensus ($8.00 target)
1
Buy3
HoldData last updated: 4/9/2026